@Jheseltineonc @vkprasadlab @VPrasadMDMPH

Does survival still matter in oncology? In this “tribute” episode, we joined w/@vkprasadlab members: definitions, examples, solutions.. all you want to know about post-protocol care and how it can distort overall survival results! We missed you, Vinay, my friend @VPrasadMDMPH!

Congratulations to the @AttardLab on the new @CellCellPress release! 🥳 @EmilyGrist1, @marina_parry and team examine associations between biological pathways and 14-year survival outcomes of patients randomized in practice-changing Phase III trials. 📝 https://t.co/huf1Xg11CV

https://t.co/QaO7WpGClW

https://t.co/yd3xCmRdrG

https://t.co/egrxHxRNrk

Adaptive RT in lymphomas ➡️ better targeting w/ reduced margins, deceased dose to OARs, adaptation to shrinking tumors, shorter course treatments, & easier treatments of multi-targets/SIBs. Read @kakumar86 @UTSW_RadOnc et al's article in the #RedJournal: https://t.co/hxcVLTjTMx

Would argue that lymphomas are one of the most important diseases to consider adaptive RT as they are exquisitely radiosensitive, often in difficult to target locations, and many have long term survival so even small decreases in dose to OARs are likely meaningful. Excited… 1/2

Honored to support the very first World Radiotherapy Awareness Day today, September 7th! 🌍 By working together, we can ensure every person facing cancer has access to life-saving radiotherapy. #WorldRTDay @CamdenClarkMC 📚 Learn more: https://t.co/2617CSWDak

📜 Perspective in Cancers: after prostatectomy, minimally invasive surgery predicted fewer acute GU/GI toxicities during salvage radiotherapy than open surgery. We explore the biology behind it. by Alessio G. Morganti, et al. @Unibo Read it here📌 https://t.co/tnPct1PxJP

📢NEW #SpecialIssue ON "Liquid Biopsies in #Gynecologic Cancer" 👨‍⚕️Guest Editors: Dr. Antonio Ieni, Dr. Vincenzo Fiorentino, and Dr. Ludovica Pepe. 🗓️Submission Deadline: 30 April 2026 ➡Look forward to receiving your submission at:  https://t.co/OYYxO3nkYY

💬Happy to share the Special issue "Tumor Microenvironment: Cellular Dynamics, Molecular Players, and Mechanisms of Therapy Resistance" edited by Dr. @Terrygag @uniud et al.👏 📆Deadline for manuscript submissions: 31 December 2026. Find more details here👉 https://t.co/37Qm0bYs8M

https://t.co/o4IaeNqXRf

Adding olaparib to neoadjuvant chemotherapy improved survival in BRCA-mutated breast cancer Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial | Nature Communications #BCSM

Watch your 💤 😴 Napping behaviors linked to increased mortality risk in middle-to-older age patients

E(gg)xciting news! Research “suggests diets including eggs, especially the yolk, may help reduce the risk of Alzheimer’s disease.”

Hereditary Cancer Predisposition Syndromes Associated with Pancreatic Cancer 10% = Genetic Predisposition Other High-Risk Groups Chr Pancreatitis: 1.8%@10y, 4%@20y Acute pancreatitis :0.4-1.4% New onset diabetes:0.5-1% >50y USPSTF recommends against screening PC in the gen pop.

Diffuse midline glioma harboring an H3 K27M mutation who have experienced disease progression following prior therapies Dordaviprone = first FDA-approved systemic therapy specifically targeting H3 K27M mutation Recommended dose of dordaviprone is 625 mg orally once weekly

ctDNA in CRC with @KristenCiombor! Here we discuss: -recent MRD trials (DYNAMIC III, etc) -endpoints -current NCCN recs -how she uses ctDNA in clinic & approaches discussion w pts As always, Kristen has such thoughtful/balanced responses to tough q’s. Full video link below

Finally MonarchE got OS after 7 years . It will be intresting to see magnitude of Benifit. Looking forward to the data . @OncoAlert @brunolarvol @dr_yakupergun @medicalwatchBC